Browse Articles

Discover research articles across all indexed journals

Relationship between androgen deprivation therapy and kidney function in patients with prostate cancer: An analysis of the RADICAL-PC study.

Journal of Clinical Oncology Geethan Baskaran, Jehonathan H. Pinthus, Celestia S. Higano et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.115

115 Background: Androgen deprivation therapy (ADT) is an effective treatment for patients with advanced prostate cancer (PC). However, its impact on renal function remains underexplored. We evaluated the impact of ADT on kidney function in a cohort of patients with PC. Methods: We analyzed the RADICAL-PC study (Role of Androgen-Deprivation Therapy in Cardiovascular Disease—A Longitudinal Prostate Cancer study, NCT04127631), a prospective study of patients with PC in 10 countries. ADT use was assessed at baseline and follow-up visits. We quantified kidney function using glomerular filtration rate (GFR), calculated using the CKD-EPI equation and creatinine measurements obtained at annual visits. We used a linear mixed-effects regression model to analyze the association between ADT and change in GFR (ΔGFR), adjusting for age, diabetes, hypertension, renal disease, heart failure, chemotherapy, medications, alcohol use, and smoking. Using a Cox regression model, we assessed the association between ADT and acute kidney injury (AKI) as reported by sites. Results: Our analysis included 4119 participants with a median age of 68 (IQR 63-74) years. In 1791 (43%) participants using ADT at baseline, the ΔGFR over 2 years was -0.64 [95%CI -1.05 to -0.22] ml/min/1.73m 2 /year. In 2328 (57%) ADT-naïve participants at baseline, the ΔGFR was -1.00 [95%CI -1.34 to -0.64] ml/min/1.73m 2 /year. There was no significant difference in ΔGFR between the two groups (p=0.20). Age (β=-0.58, p<0.001), hypertension (β=-1.98, p<0.01), and anticoagulation use (β=-3.92, p<0.001) were associated with GFR decline. When analyzed as a time-varying covariate, ADT use was associated with less GFR decline than no ADT use (-0.21 vs. -1.07 ml/min/1.73m 2 /year, respectively, p<0.01). Duration of ADT use was not associated with ΔGFR (+0.04 [95%CI -0.02 to 0.10] ml/min/1.73m 2 /month, p=0.18). AKI developed in 91 (2.2%) participants over a median follow-up of 25 (IQR 12-36) months. Baseline ADT use was associated with an increased risk of AKI in univariate analysis (HR 2.58 [95%CI 1.67 to 3.98], p<0.001), but was not significant after adjustment for covariates (HR 1.37 [95%CI 0.83 to 2.26], p=0.22). Conclusions: This analysis suggests that ADT use is not associated with GFR decline or AKI incidence in patients with PC, challenging previous literature concerning ADT-related renal dysfunction. Further studies with longer follow-up periods are needed to confirm these findings.

Natural history and risk-stratification of biochemical recurrence in prostate cancer treated with definitive radiotherapy.

Journal of Clinical Oncology Paul Riviere, Kylie Margaret Morgan, Tyler Nelson et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.348

348 Background: Biochemical recurrence (BCR) of prostate cancer following radiation therapy often does not result in clinically significant events, but a subset of patients may be at higher risk of developing metastatic disease or death. Identifying these patients is critical for clinical decision making, but unlike in the post-prostatectomy setting, no method has been externally validated for BCR after radiation therapy. This study characterized outcomes after post-radiation BCR and validated a proposed risk stratification heuristic. Methods: This was a retrospective, multicenter, nationwide cohort study of patients having post-radiation BCR treated in the United States Veterans Administration Health System. High-risk post-radiation BCR was defined as either Gleason score ≥8 or BCR occurring within 18 months of radiation therapy. BCR was defined as post-treatment PSA greater or equal to PSA nadir + 2 ng/ml, initiation of androgen deprivation therapy distinct from the initial treatment course, or development of metastatic disease, whichever occurred first. Results: Median time to BCR was 42.5 months (interquartile range 22.9-73.0). Among 7,126 patients who experienced BCR, 35.5% of patients developed metastatic disease and 17.4% died of prostate cancer at 10 years. 38.5% of patients had at least one qualifying high-risk feature of whom 23.3% had high-risk recurrence based on time to recurrence alone, 57.6% based on Gleason/Grade Group alone, and 19.1% based on both criteria. High-risk BCR resulted in higher 5-year rates of metastatic disease (42.0% versus 24.5%, hazard ratio (HR) 1.83, 95% confidence interval (CI) 1.69-1.98, p < 0.001), death from prostate-cancer (18.7% versus 8.78%, HR 1.82, 95% CI 1.63-2.03, p < 0.001), and death from all causes (37.1% versus 30.8% rates, HR 1.18, 95% CI 1.11-1.26, p < 0.001). Conclusions: A simple, two-element risk stratification tool using existing clinically data is the first validated tool for identifying patients at risk of metastases or PCSM following post-radiation BCR. Most patients experiencing BCR in this context do not develop metastases or lethal prostate cancer, making such stratification essential for treatment decision-making and refinement of patient populations for clinical trials. Further work remains on risk-adapted therapy intensification.

Progressive T cell exhaustion and predominance of aging tissue associated macrophages with advancing disease stage in penile squamous cell carcinoma.

Journal of Clinical Oncology Hiroko Miyagi, Xiaoqing Yu, Taylor Peak et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.11

11 Background: Penile squamous cell carcinoma (PSCC) is a rare malignancy with limited understanding of the tumor immune microenvironment (TIME). The interplay between PSCC and the immune system across disease progression and HPV infection status remains poorly characterized. This study aims to assess the TIME changes from localized to advanced disease and between HPV-positive versus negative tumors, we hope to identify potential immune evasion mechanisms for advanced PSCC. Methods: scRNA-seq was performed on ten PSCC tissue samples from penile, lymph node and distant metastatic sites with four matched penile and lymph node samples to understand the cellular heterogeneity within PSCC tumors. Analysis of immune cell populations and transcriptional hallmarks were performed stratified by localized (pT1-3, N0) versus advanced (N1-3, M0 or any N, M1) disease states and HPV infection status. Results: Patients with advanced stage disease were found to have a TIME enriched with terminally exhausted C8+ T cells. The myeloid compartment showed an increase in aging and immunosuppressive M2-like macrophages. Additionally, hypoxia-induced response patterns were more pronounced in advanced stages. HPV-negative tumors exhibited a quiescent TIME characterized by low immune cell infiltration. Conclusions: We observed significant differences in immune cell infiltration between localized and advanced PSCC disease states. Advanced disease states demonstrated an exhausted immune phenotype, characterized by terminally exhausted CD8 + T cells, M2-like macrophages and hypoxic signature. HPV-negative tumors displayed low immune cell infiltration. These findings offer valuable insights into the evolving PSCC immune landscape, paving the way for the development of potential novel macrophage directed therapies for PSCC.

Trajectory analysis of hepatic stellate cell differentiation reveals metabolic regulation of cell commitment and fibrosis

Nature Communications Raquel A. Martínez García de la Torre, Julia Vallverdú, Zhenqing Xu et al. Feb 10, 2025 DOI: 10.1038/s41467-025-56024-4

Nectin-4 targeted ADC, SHR-A2102, in patients with advanced or metastatic urothelial carcinoma: A phase 1 study.

Journal of Clinical Oncology Bixia Tang, Xinan Sheng, Jun Guo et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.657

657 Background: SHR-A2102 is a novel ADC that consists of a fully humanized IgG1 monoclonal antibody targeting nectin-4, a cleavable linker, and a topoisomerase I inhibitor payload with high membrane permeability and potent cell-killing efficacy. We have initiated a first-in-human phase 1 study to assess the safety, tolerability, and efficacy of SHR-A2102 in advanced solid tumors. Here, we present preliminary findings, focusing on urothelial carcinoma. Methods: Patients (pts) with locally advanced unresectable or metastatic urothelial carcinoma, who had failed or were intolerant to standard therapies, were eligible. SHR-A2102 was given intravenously at 1, 2, 4, 6, 8 mg/kg on D1 Q3W and 4 mg/kg on D1 and D8 Q3W during dose escalation. 6 and 8 mg/kg were selected for dose and efficacy expansions. Results: As of Aug 2, 2024, 73 UC pts were enrolled (median age: 65 yrs; ≥2 lines of prior systemic therapies: 57.5%; prior ADC: 42.5%). Efficacy outcomes were summarized in Table. Confirmed ORR was 38.4% (28/73; 95% CI, 27.2–50.5) in all pts, and was 32.3% (10/31; 95% CI, 16.7–51.4) in the 6 mg/kg dose group and 50.0% (16/32; 95% CI, 31.9–68.1) in the 8 mg/kg dose group. 6-mo DoR rate was 59.3% (95% CI, 23.1–83.0) in all pts, and was 66.7% (95% CI, 5.4–94.5) and 54.0% (95% CI, 12.7–83.2) in the 6 and 8 mg/kg groups, respectively. Of note, 31 pts had received ADC prior to study treatment; among them, 12 (38.7%; 95% CI, 21.9–57.8) pts achieved confirmed PR. Overall, TRAEs of grade 3 or worse occurred in 32 (43.8%) pts, with the most common (≥10%) being anemia (23.3%), decreased WBC count (19.2%), and decreased neutrophil count (17.8%). Conclusions: SHR-A2102 showed promising anti-tumor activity in pts with advanced or metastatic urothelial carcinoma, even after ADC therapy, along with manageable safety profile. Clinical trial information: NCT05735275 . Efficacy summary. All UC pts(N=73) 6 mg/kg(N=31) 8 mg/kg (N=32) ADC pretreated pts (N=31) Best overall response, n (%) Confirmed PR 28 (38.4) 10 (32.3) 16 (50.0) 12 (38.7) SD 30 (41.1) 18 (58.1) 10 (31.3) 11 (35.5) PD 12 (16.4) 3 (9.7) 3 (9.4) 7 (22.6) NE 3 (4.1) 0 3 (9.4) 1 (3.2) Confirmed ORR, % (95% CI) 38.4 (27.2–50.5) 32.3 (16.7–51.4) 50.0 (31.9–68.1) 38.7 (21.9–57.8) DCR, % (95% CI) 79.5 (68.4–88.0) 90.3 (74.3–98.0) 81.3 (63.6–92.8) 74.2 (55.4–88.1) 6-mo DoR rate, % (95% CI) 59.3 (23.1–83.0) 66.7 (5.4–94.5) 54.0 (12.7–83.2) 60.0 (12. 6–88.2) 6-mo PFS rate, % (95% CI) 41.4 (23.6–58.4) 54.7 (24.0–77.4) 38.0 (13.4–62.7) 39.1 (16.6–61.3)

Germline genetic variants in cancers of the urothelial tract and association with outcomes.

Journal of Clinical Oncology Kent Kamau, Lindsey Byrne, Debasish Sundi et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.870

870 Background: Studies cite that 10-24% of patients (pts) with urothelial carcinoma (UC) have a pathogenic germline variant (var), but few have looked at association with outcomes. We aimed to identify the frequency of germline pathogenic vars (PV) in UC and hypothesized they would be associated with cancer-related outcomes. Here we present germline results from the largest reported, fully clinically annotated cohort of pts with UC. Methods: We performed a single center retrospective review of all pts with a diagnosis (dx) of bladder, renal pelvis, ureter, or urethra cancer who underwent clinical germline targeted panel genetic testing from 2018 to 2024. We also included all pts with the same dx enrolled on an institutional protocol that performed germline whole exome sequencing (WES) for research. We analyzed the 77 genes from WES most frequently included in the targeted panels. We classified all vars as pathogenic, variant of unknown significance (VUS), or benign. Results: We included 267 pts. Median number of genes tested was 77 (range 1-93) with 83.9% of pts completing a panel of ≥77 genes. Of 267 pts, 48 (18%) had a PV, 138 (52%) had a VUS without a PV, and 81 (30%) had no germline var. The most common PVs were in CHEK2 (n = 5/48 [11%]), ATM (9%), MUTYH (9%), MSH2 (9%), TP53 (7%) and MLH1 (7%). Among the 48 pts with a PV, 12 (25%) had Lynch syndrome and 25 (52%) had a non-Lynch DNA Damage Repair gene var. Of 256 pts with urothelial histology, 47 (18%) had a PV. Of 7 pts with pure squamous histology, 1 (14%) had a PV in ATM , 4 (57%) had a VUS. Three pts with rare histologies of small cell, rhabdomyosarcoma, and adenocarcinoma had a VUS in ATM, RET, or POLD1, respectively. Of 48 pts with a PV, only 12 (25%) ever developed metastatic disease. Comparing pts with PVs (n=48) to not (n=219), we found no significant difference in median age at dx, age at dx ≥ 60, sex, race, ethnicity, smoking history, median number of 1 st degree family members with a dx of cancer, or clinical stage at dx. Pts with a PV had no significant difference in primary tumor location, however pts with Lynch syndrome were more likely to have an upper tract tumor (p = 0.002). Adjusting for clinical stage, there was no significant difference in overall survival between pts with a PV compared to without. Three of 12 pts with Lynch received an immune checkpoint inhibitor (ICI) for non-muscle invasive, muscle invasive, or metastatic disease, respectively, and all had prolonged responses without recurrence at 44, 12, and 70 months of follow-up. Conclusions: Germline PVs were detected in 18% of pts with UC. We confirmed the association of Lynch syndrome with upper tract disease and favorable response to ICI. Germline genetics of rare histologic variants warrants further investigation. Our findings support genetic testing in all pts with UC, including early-stage disease. Further study of ICIs for early-stage UC in Lynch syndrome is needed. Analysis of a larger cohort and response to specific treatments is ongoing.

PSMA-based PET imaging in newly diagnosed, high-risk localized prostate cancer, a National Cancer Institute (NCI) Cancer Moonshot trial.

Journal of Clinical Oncology Nikhil Pramod, Baris Turkbey, Peter Choyke et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.327

327 Background: Prospective randomized trials have suggested that prostate specific membrane antigen (PSMA)-based PET/CT may improve the detection of metastatic disease in patients with high-risk prostate cancer (HR-PCa) diagnosed by conventional imaging. Of patients with HR-PCa who undergo radical prostatectomy (RP), the majority will experience PSA recurrence within 5 years. PSMA-based PET/CT may improve patient selection for local therapy, suggesting that this imaging advancement may be integral to improving patient outcomes. Here, we present results from the NCI cohort of NCT03976843, which evaluated the use of 18F-DCFPyL PSMA- PET/CT in newly diagnosed HR-PCa prior to RP. Methods: Enrolled patients (pts) had HR-PCa (biopsy Gleason score [GS] ≥8, PSA >20, or ≥T3) with negative conventional imaging (CT & bone scan). Pts underwent 18F-DCFPyL PSMA PET/CT and prostate MRI prior to RP. The primary hypothesis was that the subgroup of patients with a negative pre-operative PET/CT would have improved progression-free survival (PFS) over historical controls. Progression was defined as a confirmed PSA ≥ 0.2 ng/mL and PET/CT at progression. Correlatives included IHC of RP specimens and expert NCI radiologic imaging review. Results: Forty patients enrolled, and 38 patients underwent RP. Of the 38, the median age was 68 years old (61-71 years old), median PSA was 8.15 ng/mL (5.75-16.25), median biopsy GS was 8 (8-9), and median RP GS was 7 (7-8). Pre-operative PET/CT demonstrated regional lymphadenopathy in 2 patients (5.3%), and the median SUVmax of the index lesion was 12.6 (6.6-17.1). At a median follow-up of 2.2 years, the 2- and 4-year PFS was 76% (63%-91%) and 45% (22%-95%), respectively. The median PFS was 3.2 years. Of the 11 pts who underwent progression restaging, 2 had recurrent pelvic nodal disease, and 9 had no visible disease. No AEs were observed. Conclusions: These results support 18F-DCFPyL PET/CT as a safe and effective pre-operative staging strategy with the potential to improve patient selection for local definitive therapy. Expert NCI radiologic review for this multisite study, with correlative molecular and genomic work, is ongoing. Clinical trial information: NCT03976843 .

Integrated efficacy and safety exposure response (ER) analysis of tivozanib (TIVO) for the treatment of renal cell cancer (RCC).

Journal of Clinical Oncology Bradley Alexander McGregor, Toni K. Choueiri, Laurence Albiges et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.461

461 Background: TIVO is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) approved in the US for treatment of patients with RCC following ≥2 prior systemic therapies. The approved TIVO monotherapy starting dose is 1.34 mg once daily on days (D) 1-21 Q28D, with allowable dose modifications to manage adverse events. In the randomized TiNivo-2 trial, the addition of NIVO 480 mg to TIVO 0.89 mg D1-21 Q28D (lower dose of TIVO was studied given assumed risk of hypertension [HTN]) did not improve outcomes compared with TIVO 1.34 mg D1-21 Q28D. There was a trend toward worse progression-free survival (PFS) in the combination arm. Methods: Using a predeveloped population pharmacokinetic (PK) model, existing ER models based on Tivo-1 and Tivo-3 studies were augmented to characterize the relationship between TIVO at clinically relevant exposures and central reviewer–based PFS, tumor size (TS) reduction, and safety endpoints. TiNivo-2 trial results were integrated to update the PK and ER models for PFS (Cox proportional hazard), TS (sum of longest diameters longitudinal model), and HTN (logistic regression) and to simulate the ER-based risk/benefit profile of TIVO. Results: The visual predictive check of the PK model on TiNivo-2 PK data confirmed that the dose-proportional TIVO PK is unaffected by concurrent NIVO. The PFS range of 5.6-9.7 months and TS reduction models, with a range of −7.02% to −23.8%, showed a significant relationship with TIVO exposure (Table). Concurrent NIVO did not add discernible benefit to TIVO at the dose of 0.89 mg. An ER modeling analysis between maximum concentration and HTN showed that the predicted HTN incidence was similar between TIVO 1.34 mg and TIVO 0.89 mg (41.3% vs 38.8% for any-grade HTN; 23.8% vs 21.5% for grade ≥3 HTN). An effect term for NIVO in the ER model for HTN was nonsignificant. Conclusions: The efficacy ER models predicted that TIVO 1.34 mg would provide greater antitumor activity than the 0.89-mg dose, while the predicted HTN incidence (any grade and grade ≥3) was comparable at the 0.89- and 1.34-mg doses. The TIVO monotherapy dose selection of 1.34 mg is important, based on the ER analysis and its safety profile. The results from the TiNivo-2 data set further confirmed that re-challenge with immunotherapy does not add benefit and optimal dosing of TKI provides the highest clinical benefit. Clinical trial information: NCT04987203 . Efficacy endpoint TIVO average concentration, ng/mL n Observed value,combined studies (range) PFS 13.9-38.4 192 5.6 months PFS 38.4-47.9 191 7.3 months PFS 47.9-62.0 191 9.1 months PFS 62.0-177 191 9.7 months CFB TS 13.9-38.4 176 −7.02% (−16% to 1.93%) CFB TS 38.4-47.9 173 −11.7% (−21.3% to −2.05%) CFB TS 47.9-62.0 185 −17.3% (−26.4% to −8.27%) CFB TS 62.0-177 183 −23.8% (−33.5% to −14.1%) CFB, change from baseline.

Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom’s Macroglobulinemia

Nature Communications Romanos Sklavenitis-Pistofidis, Yoshinobu Konishi, Daniel Heilpern-Mallory et al. Feb 10, 2025 DOI: 10.1038/s41467-025-56323-w

Real-world time on treatment (rwTOT) with first-line (1L) enfortumab vedotin and pembrolizumab (EV+P) after U.S. Food and Drug Administration approval for advanced urothelial cancer (aUC).

Journal of Clinical Oncology Melanie Mayer, Nicholas Seewald, Ernesto Ulloa Perez et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.731

731 Background: EV+P received accelerated approval (AA) for cisplatin (cis)-ineligible aUC patients in April 2023 (EV-103) and full approval (FA) for all previously untreated patients in December 2023 (EV-302). In EV-302 trial, median durations of treatment with EV+P was 9.4 months (7.0 and 8.5 months for EV and P, respectively). We previously demonstrated high uptake of EV+P post AA in the real-world. Here, we examine rwToT with 1L EV+P with nearly 1 year of follow-up post-AA. Methods: This descriptive, post-marketing, retrospective cohort study used the Flatiron Health longitudinal database derived from EHR records of US patients with aUC initiating 1L EV+P after April 5, 2023 (AA) but before December 15, 2023 (FA). rwToT for EV+P was defined as length from first administration date of EV+P regimen to 1L therapy discontinuation, defined as last administration date of either component (i.e., EV or P) if patient initiated a next line of therapy, died during therapy, or had a gap of >60 days between last recorded dose and last contact date. rwToT was also estimated for each EV+P component. If no discontinuation criteria were met, the patient was censored at data cut-off (March 31, 2024). The Kaplan-Meier method was used for analysis of rwToT, including median rwToT (months) and 30-, 90-, 180-day on-treatment rates (%). Results: We identified 111 patients with aUC who initiated 1L EV+P after AA but before FA (mean age: 73.9 y, 75.7% male, 77.0% white, 23.7% ECOG performance status ≥2, 75.2% cis-ineligible, and 84.7% from community practices). As of March 31, 2024, approximately 41.4% (n=46) discontinued both EV and P; 9.9% [n=11] began subsequent therapy, 27.0% [n=30] died, and remaining patients were censored at end of follow-up (58.6%, n=65). Median rwToT (95% confidence interval [CI]) for EV+P, EV, and P were 8.2 months (6.5-not reached [NR]), 7.2 months (5.2-NR), and NR (6.3-NR), respectively (on-treatment rates reported in Table). Among 1L EV+P treated patients receiving subsequent therapies, 72.7% (9/11) received gemcitabine and carboplatin as the first subsequent therapy. Conclusions: In this large and predominantly cis-ineligible cohort of advanced urothelial cancer patients treated with EV+P in contemporary practice, rwTOT approximated duration of treatment in clinical trials. Most 1L EV+P users receiving subsequent anticancer therapy received platinum-based chemotherapy. rwToT with 1L EV+P for patients with advanced urothelial cancer (N=111). EV+P EV P Discontinued, n (%) 46 (41.4) 52 (46.8) 47 (42.3) Censored, n (%) 65 (58.6) 59 (53.2) 64 (57.7) Median rwToT, months (95% CI) 8.1 (6.4-NR) 7.1 (5.1-NR) NR (6.2-NR) On-treatment rate, % (95%CI) 30-d 84.7(78.2, 91.7) 82.0(75.1, 89.5) 81.1(74.1, 88.7) 90-d 72.1(64.2, 80.9) 65.8(57.5, 75.2) 72.1(64.2, 80.9) 180-d 60.4(51.4, 70.9) 54.0(45.0, 64.9) 60.0(51.1, 70.4)

A phase II trial of dostarlimab and niraparib combination therapy in patients with stage III-IV recurrent or refractory penile cancer.

Journal of Clinical Oncology Gabriel Roman Souza, Curtis Alvin Pettaway, Matthew T. Campbell et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps14

TPS14 Background: Penile squamous cell carcinoma (PSCC) is a rare and aggressive malignancy with limited therapeutic options, particularly for patients whose disease progresses despite platinum-based chemotherapy. The overall survival rate for these patients is less than five months with standard treatment, highlighting the critical need for new and effective therapies. Preclinical studies have demonstrated a synergistic effect between PARP inhibitors and immune checkpoint inhibitors in PSCC animal models. The combination of niraparib and dostarlimab holds promise in eliciting a robust antitumor immune response in patients with cisplatin-refractory PSCC. Methods: This is an open-label, multi-center, phase II study employing a Simon two-stage design to assess the efficacy and safety of niraparib and dostarlimab in patients with advanced relapsed or refractory PSCC. Patients must provide an adequate tumor tissue sample at screening for molecular and immune profiling. Blood samples are collected at cycle 1, day 1 (C1D1) for exploratory molecular analysis, at cycle 3, day 1 (C3D1), at the time of investigator-assessed partial response (PR) or complete response (CR), and at the end-of-treatment visit. Niraparib will be administered orally at a dose of 200 mg once daily from day 1 to day 21 of each cycle, continuing until disease progression or unacceptable toxicity. Dostarlimab will be administered intravenously once every three weeks for cycles 1 through 4 and then every six weeks thereafter. Eligible patients must have histologically confirmed stage III (unresectable) or stage IV penile cancer as defined by the American Joint Committee on Cancer (AJCC) staging system. They must have experienced disease progression or intolerance after one line of platinum-based therapy, possess a life expectancy of at least 12 weeks, and have an ECOG performance status (PS) of 0 or 1 (patients with an ECOG PS of 2 may be included upon discussion with the principal investigator). Additional eligibility criteria include measurable disease according to the Immune-Modified Response Evaluation Criteria in Solid Tumors (iRECIST), adequate organ function, and no prior treatment with immunotherapy agents, cancer vaccines, adoptive cell therapies, or cytokine therapies. The primary efficacy endpoint is the investigator-assessed confirmed overall response rate (ORR), with tumor response evaluated according to iRECIST criteria. Patients who receive at least one complete dose of either study drug will be considered evaluable for response. Secondary endpoints include progression-free survival (PFS), overall survival (OS), and duration of response (DOR), safety, and tolerability. Enrollment began in December 2022, and 14 of the planned 25 patients have been enrolled. Clinical trial information: NCT05526989 .

Functional and oncological outcome of primary nerve sparing retroperitoneal lymph node dissection in marker negative testicular germ cell tumors in clinical stage IIA/B.

Journal of Clinical Oncology Julian Heidenreich, Axel Heidenreich Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.641

641 Background: Guideline recommended treatment of choice for clinical stage IIA/B testicular nonseminomatous germ cell tumors (NSGCT) is the delivery of chemotherapy with 3 cycles PEB, 4 cycles PE. Despite its high curative efficacy, chemotherapy is associated with significant long-term toxicities. We evaluated the functional and oncological outcome of primary nerve sparing retroperitoneal lymph node dissection in marker negative NSGCT as a therapeutic option. Methods: Between 2018-2024 49 patients underwent primary RPLND for marker negative clinical stage IIA/B testicular germ cell tumors. All patients underwent nerve-sparing RPLND with a unilateral or bilateral template dissection. None of the patients received adjuvant chemotherapy. Follow-up was performed according to the EAU guidelines. The surgeries were performed by a single surgeon using an open transperitoneal approach. Results: The median age and median follow-up were 30.1 (17-35) years and 29.4 (11-47) months, respectively. The mean operative time, blood loss, and hospitalization duration were 131 (105-195) minutes, < 150ml, and 4.5 (3-9) days, respectively. 10 patients (9.18%) experienced a Clavien-Dindo grade 3a complication. Antegrade ejaculation was preserved in 90.8% of cases. On average, 21 (7-42) lymph nodes were dissected. 5 patients exhibited teratomatous elements in the primary orchiectomy specimens and 4 patients demonstrated teratomatous elements in the resected lymph nodes. The mean number of positive lymph nodes was 2 (1-3), with an average size of 1.3 (0.3-3.0) cm. Ten patients (20.4%) showed a pN0 stage. Six patients (12.2%) developed a recurrence and were cured by salvage chemotherapy. Conclusions: Primary RPLND for marker negative clinical stage II/ABnonseminomatous germ cell tumors results in a high cure rate without additional chemotherapy and it is associated with a low rate of complications if performed in experienced hands. Additionally, nsRPLND can safe unnecessary cytotoxic systemic therapy in 20% of patients. Furthermore, 8.1% of patients with teratoma containing lymph nodes would not have been cured by chemotherapy. Primary nsRPLND should be included in the management of marker negative CS IIA/B NSGCT.

Spatial transcriptomic analysis of tumor tissue from patients with metastatic urothelial carcinoma (mUC) receiving ipilimumab (IPI) plus nivolumab (Nivo) combined with sacituzumab govitecan (SG).

Journal of Clinical Oncology Faustine Ong, Jin Xu, Yonghong Zhang et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.863

863 Background: We previously reported that the combination of IPI-NIVO plus SG shows high efficacy with 83.3% objective response rate (ORR) and durable responses as first-line treatment for cisplatin-ineligible mUC patients in a Phase I/II trial. However, two grade 5 immune-mediated myocarditis events attributed to IPI-NIVO occurred, leading to early trial termination after accruing 25 patients. Given the high ORR, we performed correlative analysis to identify a predictive biomarker for response. Methods: For Nanostring GeoMx DSP spatial transcriptomics, 19 baseline tumor samples were evaluable. Patients were categorized as responders (CR+ PR, n=15) and non-responders (SD+ PD, n=4). The raw Nanostring GeoMx probeQC count data was quality-controlled for both segment and gene levels using GeomxTools package in R version 4.3. The segments with flags such as ‘Low Percent Aligned Reads’, ‘Low Percent Stitched Reads’, ‘Low Surface Area’, ‘Low Nuclei Count’, ‘Low Negative Mean’, and ‘Low gene detection rate’ were excluded from further analysis. In total, 35 and 24 segments were left for responder and non-responder groups, respectively. Genes with raw count smaller than the ROI-specific limitation of quantification (LOQ) and low detection rate among segments were excluded from downstream analysis. Totally, 8230 genes were left for 59 segments for further analysis. The differential expression between groups was done using a linear mixed-effect model. Results: 90 and 136 genes were significantly up- and down-regulated in responder group and non-responder group (P value < 0.05 for both). The top upregulated genes in responders included: IGHG2, IGKC, ACKR2, KRT80 and SCD, while those upregulated in non-responders included: S100A2, AKR1C3, MYCN, MAGEA3, and OBSCN (P value < 0.05) . Gene set enrichment analysis (GSEA) revealed gene signatures from B cell-mediated immunity pathway significantly enriched in the responder group (FDR = 0.02), while gene signatures from PRC2_EZH2_UP.V1_DN related to polycomb-mediated transcription reprogramming and promoting tumorigenesis were significantly enriched in the non-responder group (FDR = 0.0017). Trop2 and Topoisomerase 1 genes were upregulated in responders but not statistically significant. Conclusions: Spatial transcriptomics analysis suggests that upregulated B cell-mediated immunity pathways may predict response to combination IPI-NIVO + SG in patients with mUC. The PRC2-EZH2 pathway may represent a potential resistance mechanism and therapeutic target. Transcriptomic evaluation of the therapeutic targets of the antibody and the payload in antibody-drug conjugates warrant further study as predictive biomarkers. Further analyses to identify biomarkers for severe immune events may help optimally select patients for the best therapeutic index. Clinical trial information: NCT04863885 .

Author Correction: Medical history predicts phenome-wide disease onset and enables the rapid response to emerging health threats

Nature Communications Jakob Steinfeldt, Benjamin Wild, Thore Buergel et al. Feb 10, 2025 DOI: 10.1038/s41467-025-56429-1

Retrospective, observational analysis of real-world safety outcomes in sacituzumab govitecan (SG)-treated patients (pts) with locally advanced/metastatic urothelial cancer (la/mUC).

Journal of Clinical Oncology Mamta Parikh, Peter McMahon, Susan Eng et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.709

709 Background: In the rapidly evolving la/mUC treatment landscape, new therapies need to be integrated into management of pts. SG, a Trop-2–directed antibody drug conjugate, showed improved overall survival and manageable safety in pts with la/mUC who progressed on platinum-based chemotherapy and immune checkpoint inhibitor therapy in TROPHY-U-01 (NCT03547973). Safety of SG was previously reported in a retrospective cohort study using US Flatiron Health electronic health record–derived de-identified database of pts ≥ 18 yrs with la/mUC initiating SG from Dec 2019 - Oct 2022. We now present results from the expansion cohort with an additional year of follow-up. Methods: Pts in the expansion cohort had initiated SG from Dec 2019 - Jul 2023. Data on treatment (tx) patterns, abstracted adverse events (AEs) of interest (AEs chosen a priori based on what was observed in clinical studies), tx discontinuation, hospitalization, and granulocyte colony-stimulating factor (G-CSF) use were summarized using descriptive statistics. Results: Of 220 SG-treated pts (male, 73%; median age, 66 yrs), most (63%) received enfortumab vedotin (EV) monotherapy in the prior tx line. The most common AEs of interest were diarrhea (n = 110 [50%]), neutropenia (n = 77 [35%]), and nausea (n = 76 [35%]). Febrile neutropenia and infections secondary to neutropenia occurred in 18 (8%) and 9 (4%) pts, respectively (Table). Of the 220 pts, 141 (64%) had a documented reason for SG discontinuation; 106 (75%) pts discontinued due to disease progression and 19 (13%) due to AEs/toxicities. Of these latter 19 pts, 3 each (16%) discontinued due to neutropenia and fatigue. Discontinuation rate based on prespecified AEs of interest occurring during therapy was 3% (n = 7). Of the 220 pts, 62 (28%) were hospitalized due to AEs. During SG tx, 104 (47%) pts received G-CSF at any time; 64 (29%) received G-CSF primary prophylaxis. Of 79 pts with neutropenia onset during SG index line, 14 (18%) received G-CSF primary prophylaxis, 29 (37%) received secondary prophylaxis and 36 (46%) received G-CSF treatment. Conclusions: This is the largest analysis to date of SG use in a real-world population with la/mUC, with a significant number of EV-pretreated patients. Although AEs such as diarrhea, neutropenia, and nausea occurred frequently, tx discontinuation rate (based on prespecified AEs) was low. Observed AEs were consistent with the known safety profile of SG. Incident AEs of interest, n (%); (N = 220). Anemia 36 (16) Neutropenia 77 (35) Febrile neutropenia | Infections secondary to neutropenia a 18 (8) | 9 (4) Sepsis 25 (11) UTI 34 (15) Diarrhea 110 (50) Nausea | Vomiting 76 (35) | 41 (19) Stomatitis 21 (10) Fatigue 52 (24) Infusion-related reaction 1 (<1) a Prevalent numbers are reported since baseline status was not abstracted for these events.

Evaluating disparities in prostate cancer-related mortality among diabetic adults in the United States and Texas: A 21-year observational study (1999-2020).

Journal of Clinical Oncology Sidra Naz, Hira Naz, Kashif Ali et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.30

30 Background: The prostate cancer (PCa) mortality risk with diabetes is poorly understood and understudied. We aim to study the annual trends and sociodemographic factors in prostate cancer-related mortality among diabetic individuals in the United States and its state of Texas from 1999 to 2020 to evaluate public health initiatives and offer insights for improving patient outcomes. Methods: Mortality trends in PCa among diabetic adults aged ≥25 years were analyzed using the CDC WONDER database, identifying through ICD-10 codes C61 “Prostate Malignant neoplasms” and E14 “Diabetes Mellitus”. Crude and age-adjusted mortality rates (AAMRs) per 100,000 people were extracted. Annual percent changes (APCs) in AAMRs, with 95% confidence intervals, were determined using joint point regression analysis across various demographic (sex, race/ethnicity, age) and geographic (state, urban-rural, regional) subgroups. Results: Between 1999 and 2020, 4477954 documented deaths were attributed to PCa associated with diabetes. The overall AAMR for PCa-related mortality in diabetic adults decreased in the US from an adjusted rate (AR) 109.8 in 1999 to (79.1) in 2018 (APC: -1.84%; 95% CI: -2.22% to -1.58%), then it increased to 100.4 in 2020 (APC: 10.4%; 95% CI: 2.97% to 13.4%). In Texas, AAMR for PCa among diabetic adults decreased from AR 125.5 in 1999 to 93.9 in 2018 (APC: -1.71%; 95% CI: -2.25% to -1.26%), after which it increased to 126.6 in 2020 (APC: 14.3%; 95% CI: 4.83% to 18.9%). The AAMR in U.S. men decreased from 166.8 in 1999 to 119.1 in 2018 (APC: -1.96%; 95%CI: -2.34% to -1.68%) and then increased to 147.7 in 2020 (APC: 9.66%; 95% CI: 2.66% to 12.7%). The non-Hispanic (NH) Black or African American (AA) population has the greatest AAMR (191.6), followed by the NH American Indian or Alaska Native (166.2) and the Hispanic or Latino population with AAMR (117.8). The lower-risk population was NH White with AAMR (87.2) and NH Asian or Pacific Islander (59.1). AAMR also varied by region (South: 116.5; Midwest: 101.2; Northeast: 95.5; West: 75.9), and non-metropolitan areas had higher AAMR (small metro: 100.6; micropolitan: 119.9; non-core areas: 124.3) than metropolitan areas (large central metropolitan: 102.2; large fringe areas: 84.8). The states in the upper 90th percentile of AAMRs were Oklahoma, Louisiana, Mississippi, Kentucky, Ohio, West Virginia, Maryland exhibited an approximately two-fold increase in AAMRs, compared to states falling in the lower 10th percentile i.e Nevada, Kansas, Arizona, Florida, MA, Wyoming, and Colorado. Conclusions: Mortality rates from prostate cancer among diabetic adults have risen in the United States and Texas over the past two decades. However, NH Black or AA, NH American Indian or Alaska Native, Hispanic or Latino men are at more risk than NH White and NH Asian or Pacific Islander.

EMETPRO: A multicenter, international, retrospective analysis evaluating patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) with early progression (EP).

Journal of Clinical Oncology Fabio Turco, Martino Pedrani, Giuseppe Salfi et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.169

169 Background: Combination therapies, such as androgen deprivation therapy (ADT) + androgen receptor pathway inhibitor (ARPI) +/- docetaxel, were shown to improve overall survival (OS) in pts with mHSPC. However, some pts are still characterized by EP. EMETPRO study analyzed these pts and their response to treatments administered at progression. Methods: EMETPRO is a multicenter, retrospective registry of pts with EP mHSPC defined as pts who have progression ≤ 6 months (m) under combination therapies (ADT + docetaxel or ADT + ARPI) or ≤ 9 m from ADT alone start. The primary endpoint is progression-free survival (PFS) calculated from the start of first-line (1°L) treatment for mCRPC in the entire population and in the different treatments sub-cohorts based on the treatment received in mHSPC. Secondary endpoints included OS calculated from the start of treatment for mHSPC and from the start of 1°L treatment for mCRPC. Results: From May 2005 to May 2023 431 pts were enrolled in the study. Median age was 69 years. Molecular analyses were available in 195 (45.2%) pts (Table). 206 (47.8%) pts received ADT alone for mHSPC while 123 (28.6%) and 77 (17.8%) pts received ADT + docetaxel and ADT + ARPI, respectively. 80 (38.8%) and 66 (32.0%) pts treated with ADT alone in mHSPC received ARPI or docetaxel as 1°L mCRPC treatment, respectively. 77 (62.6%) and 13 (10.6%) pts treated with ADT+ docetaxel in mHSPC received ARPI or cabazitaxel in mCRPC, respectively. 46 (59.7%) and 7 (9.1%) pts treated with ADT+ ARPI in mHSPC received docetaxel or a second ARPI in mCRPC, respectively. 14 pts (3.2%) received olaparib or radioligand treatments as 1°L mCRPC therapy. The median PFS from the start of 1°L treatment for mCRPC was 6.5, 4.9, and 5.4 m for pts that received ADT, ADT + docetaxel and ADT + ARPI, respectively. The median OS from mHSPC was 27.0, 20.0, and 19.5 m, in the same groups while the median OS from 1°L treatment for mCRPC was 18.5, 12 and 14.6 m, respectively. The 1°L therapy received in the mCRPC setting and the molecular profile did not correlate with PFS or OS. Conclusions: Pts with EP mHSPC are characterized by poor outcomes regardless of treatment received at progression. The best 1°L mCRPC therapy to use in these pts remains a crucial unmet clinical need. Future studies evaluating novel mechanisms (e.g. olaparib or lutetium PSMA) or intensification strategies (e.g. cabazitaxel and/or carboplatin) in this setting are urgently needed. Baseline characteristics. Number (N°) of pts 431 GS≥8 at mHSPC, N° (%) 278 (64.5) High-volume disease (CHAARTEED), N° (%) 302 (70.1) N° of pts with germline testing results 63 Alterations detected, N° (%) 24 (38.1) BRCA alterations detected, N° (%) 13 (20.6) N° of pts with somatic testing results 181 DNA damage response and repair gene alterations, No. (%) 47 (26.0) At least one TP53/PTEN/RB1 gene mutation detected, No. (%) 84 (46.4)

Impact of upstaging from cT2a–b to pT3a on overall survival (OS) among patients with renal cell carcinoma.

Journal of Clinical Oncology Taylor Goodstein, Rajvi R. Goradia, Arnav Srivastava et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.601

601 Background: Identifying patients with renal cell carcinoma (RCC) who may benefit from adjuvant systemic therapy has proven difficult. Approximately 40% of patients with cT2a-b tumors will be upstaged to pT3a disease following surgery. These patients, given their large tumor size, may represent a higher risk cohort compared to patients with concordant T3a staging. We assessed OS among cT2a-b patients who were upstaged to pT3a compared to their cT3a counterparts with concordant pathologic staging. Methods: Using the National Cancer Database, we identified N0M0 adult patients with cT2a, cT2b, and cT3a RCC who underwent partial or radical nephrectomy and had pT3a disease on final pathology. We categorized patients into three groups: (1) cT2a to pT3a, (2) cT2b to pT3a, and (3) cT3a to pT3a. We compared OS between the groups using Kaplan Meier estimates and multivariable analysis using Cox proportional hazards models. Subgroup analysis of overall survival was performed for histology (clear cell vs non–clear cell). Results: 11,241 patients met inclusion criteria (3,067 cT2a, 1,893 cT2b, and 6,281 cT3a). Median pathological tumor size was 8.0, 11.2, and 7.5 cm for cT2a, cT2b and cT3a tumors, respectively. Mean 5-year OS was 37% for both cT2a and cT2b disease upstaged to pT3a and 48% for cT3a disease with concordant pathological staging (log rank p < 0.0001). This finding persisted on multivariable analysis (cT3a HR 0.81 [0.77–0.85], p < 0.001). Conclusions: Patients who were pathologically upstaged from cT2 to pT3a disease had worse OS compared to patients with concordant staging, a finding likely related to differences in median tumor size. Our findings imply that it is reasonable to include well-selected cT2 tumors in the next iteration of perioperative trials. However, those designing and conducting clinical trials must power their studies to adjust for heterogeneity in pathologic restaging.

Macrocycle-based PROTACs selectively degrade cyclophilin A and inhibit HIV-1 and HCV

Nature Communications Lydia S. Newton, Clara Gathmann, Sophie Ridewood et al. Feb 10, 2025 DOI: 10.1038/s41467-025-56317-8

Abstract Targeting host proteins that are crucial for viral replication offers a promising antiviral strategy. We have designed and characterised antiviral PROteolysis TArgeting Chimeras (PROTACs) targeting the human protein cyclophilin A (CypA), a host cofactor for unrelated viruses including human immunodeficiency virus (HIV) and hepatitis C virus (HCV). The PROTAC warheads are based on fully synthetic macrocycles derived from sanglifehrin A, which are structurally different from the classical Cyp inhibitor, cyclosporine A. Our Cyp-PROTACs decrease CypA levels in cell lines and primary human cells and have high specificity for CypA confirmed by proteomics experiments. Critically, CypA degradation facilitates improved antiviral activity against HIV-1 in primary human CD4+ T cells compared to the non-PROTAC parental inhibitor, at limiting inhibitor concentrations. Similarly, we observe antiviral activity against HCV replicon in a hepatoma cell line. We propose that CypA-targeting PROTACs inhibit viral replication potently and anticipate reduced evolution of viral resistance and broad efficacy against unrelated viruses. Furthermore, they provide powerful tools for probing cyclophilin biology.

Deep prostate-specific antigen (PSA) decline among early participants (pts) in LIBERTAS, a phase 3 study of apalutamide (APA) plus continuous versus intermittent androgen deprivation therapy (ADT) in metastatic castration-sensitive prostate cancer (mCSPC).

Journal of Clinical Oncology Arun Azad, Marco Antonio Badillo, Qiang Dong et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.147

147 Background: LIBERTAS is investigating APA in combination with intermittent ADT as an ADT de-escalation strategy for patients with mCSPC. The objective is to evaluate whether APA + intermittent ADT in pts who achieved PSA <0.2 ng/mL after 6 mo initial treatment with APA + ADT provides noninferior radiographic progression-free survival (rPFS) and reduces hot flash burden compared with APA + continuous ADT. In the TITAN study, 54% (263/490) of pts with mCSPC treated with APA + ADT achieved PSA ≤0.2 ng/mL within 3 mo (1). Pts who also achieved PSA ≤0.02 ng/mL vs PSA >0.2 ng/mL showed better overall survival rates (2). Here, we present initial findings of pts enrolled early in LIBERTAS. Methods: LIBERTAS enrolled pts with mCSPC, inclusive of all gender identities. Eligible pts have ≤3 mo ADT prior to enrollment, except for pts receiving ADT as part of their gender-affirming care (GAC), and ECOG PS 0 or 1. Pts have metastasis documented by conventional imaging (CT, MRI, or bone scan) and/or regional lymph node metastases by next-generation imaging (NGI); pts undergoing GAC are eligible with or without evidence of metastasis by conventional imaging or NGI. In the initial 6-mo treatment phase, all pts receive APA 240 mg/d + ADT. In the main treatment phase, 240 pts with confirmed PSA <0.2 ng/mL after the initial treatment phase will be randomized 1:1 to APA 240 mg/d + intermittent or continuous ADT. Stratification: tumor volume and prior treatment for localized PC. Primary end points: rPFS, measured by 18-mo event-free survival rate, and reduction of hot flash burden, measured by the severity-adjusted hot flash score. Results: As of September 20, 2024, 420 pts at 73 sites in 9 countries have enrolled in the initial treatment phase, completing the enrollment goal ahead of schedule. Demographics include 70.5% White, 9.5%, Asian, and 8.6% Black. At baseline, pts had a median (range) age of 70 yrs (48-88) and median PSA 15.0 ng/mL (0.02-6000 ng/mL). At data cutoff, 87 pts had been randomized to the main treatment phase. Among 350 pts with at least 2 evaluable PSA values collected during the initial treatment phase, 246 (70.3%) achieved PSA <0.2 ng/mL and 307 (87.7%) experienced ≥90% PSA decline from baseline at some point during the initial treatment phase. Hot flash compliance, defined as the percentage of data collected per protocol across all sites and visits, exceeded 80%. No new safety signals were observed. Conclusions: Treatment with 6 mo of APA + ADT in this prospective trial resulted in deep PSA responses in the majority of pts with mCSPC. The LIBERTAS study remains on track for successful completion of expected randomization for the standard APA + ADT vs APA + ADT de-escalation. 1. Chowdhury, Ann Oncol 2023. 2. Merseburger, BJU Int 2024. Clinical trial information: NCT05884398 .